Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPT regimen for NK/T cell lymphoma
ChiCTR2500109853Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dexamethasone, azacitidine, pegaspargase and tislelizumab in natural killer/T-cell lymphoma (NKTL), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Overall response rate. Started Sep 2025; status: recruiting.
02
Drugs
dexamethasoneazacitidinepegaspargasetislelizumab
03
Conditions
natural killer/T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on ChiCTR2500109853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109853.